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To determine the role of intravenous tissue plas- 
minogen activator (t-PA) in unstable angina, it was 
compared with placebo in a randomized, double- 
blind trial. Forty patients with angina at rest and 
provocable ischemia (pacing induced) had baseline 
coronary angiography, study drug infusion and 
then repeat angiography at 20 f 9 hours. All pa- 
tients received diltiazem, nitrates, /3 blockers, 
aspirin and intravenous heparin. During study drug 
infusion (150 mg over 8 hours), refractory ische- 
mia necessitating emergency bypass surgery 
(CABG) or coronary angioplasty (PTCA) occurred 
in 4 of 20 t-PA patients compared with 1 of 20 pla- 
cebo patients (p = 0.21). Before discharge, revas- 
cularization for persistent, provocable ischemia and 
a residual stenosis 260% was as follows: t-PA pa- 
tients, 8 PTCA and 7 CABG; placebo patients, 11 
PTCA and 8 CABG (p = 0.39). Quantitative angio- 
graphic percent diameter stenosis of the culprit ar- 
tery at baseline and follow-up was: t-PA 71 f 17 
and 63 f 22; placebo 70 f 19 and 67 f 22 (differ- 
ence not significant). However, 3 t-PA patients 
compared with no placebo patients demonstrated 
an insignificant (<60% diameter) residual stenosis 
and averted PTCA (p = 0.14). There were no com- 
plications of PTCA in the 8 t-PA patients; in con- 
trast, 3 of 11 placebo patients had abrupt closure, 
necessitating emergency CABG in 2 (p = 0.23). 
Thus, intravenous t-PA in unstable angina can 
eliminate the need for PTCA in a few patients, does 
not appear to decrease the overall or emergency 
rate of revascularization procedures and may facili- 
tate the safety of PTCA. 
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T he critical importance of coronary artery thrombus in the clinical syndrome of unstable angina has been well established by recent biochemical, an- 
giographic, angioscopic and pathologic studies.1-4 De- 
spite our increased understanding of the pathophysiolo- 
gy, there has been limited experience with thrombolytic 
therapy for unstable angina5-7 and the results obtained 
to date lack agreement regarding the indications or use- 
fulness of such therapy. Since its introduction for man- 
agement of unstable angina in 198 1,8,9 percutaneous 
transluminal coronary angioplasty (PTCA) has been in- 
creasingly applied, particularly for refractory symp- 
toms. lo However, angiographically defined thrombus, a 
common feature of unstable angina and rest ischemic 
pain, has been identified as a risk factor for abrupt clo- 
sure and complications of PTCA.” Thus, the rationale 
for thrombolytic therapy in this setting extends beyond 
dissolution of intraluminal coronary artery thrombus, to 
the potential achievement or facilitation of definitive 
coronary revascularization. The current study was de- 
signed to evaluate intravenous tissue-type plasminogen 
activator (t-PA), a relatively clot-selective librinolytic 
agent with particular advantage for aged thrombus12 in 
patients with unstable angina receiving maximal medi- 
cal therapy. In this randomized, double-blind pilot trial 
report, the focus will be the need for coronary revascu- 
larization procedures and their safety following intrave- 
nous t-PA or placebo. 
METHOD5 
Patient selection: Inclusion criteria were: (1) chest 
pain at rest within 7 days judged clinically to represent 
myocardial ischemia, with or without accompanying 
electrocardiographic changes; (2) angiographically de- 
fined significant coronary artery stenosis (>60% diame- 
ter by visual estimate); (3) provocation of ischemia by 
pacing; and (4) absence of a contraindication to throm- 
bolytic therapy, left main coronary artery stenosis 
>50% or recent myocardial infarction, as indicated 
by elevation of serum creatine phosphokinase 2 times 
above normal levels. Informed consent was obtained 
before enrollment. Recruitment began on March 26, 
1986, and ended on April 1, 1987. 
Treatment protocol: Before cardiac catheterization 
5-drug medical therapy was initiated and maximized as 
follows: (1) aspirin 325 mg daily; (2) propranolol40 mg 
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4 times daily (or an alternate /?-blocking agent) or high- 
er doses to decrease resting heart rate no lower than 50 
beats/min; (3) diltiazem 60 to 120 mg 4 times daily; (4) 
intravenous nitroglycerin or oral isosorbide dinitrate ev- 
ery 6 hours (unless systolic blood pressure < 110 mm 
Hg); and (5) intravenous heparin 1,000 U/hr continu- 
ous infusion adjusted to 2 to 2.5 times the activated par- 
tial thromboplastin time. After diagnostic coronary 
angiography using the Judkins approach, transvenous 
right ventricular pacing was begun at 70 to 100 beats/ 
min and serially increased at 3-minute intervals by in- 
crements of 10 beats/min until the patient developed 
typical angina1 chest pain, significant ST-segment 
changes (>1.5 mV depression) by 12-lead electrocardi- 
ography during supraventricular rhythm between rate 
increases or until reaching a rate of 150 beats/min. 
Femoral arterial and venous sheaths were left in place 
for repeat angiographic and pacing studies. 
Patients fulfilling entry criteria were randomly allo- 
cated to receive t-PA or placebo by a random number 
sequence developed by Genentech, unknown to the in- 
vestigators, until the completion of the trial and all data 
entry. The study drug vials were physically identical 
and a sealed envelope, containing a scratch-away film 
card, were provided for each patient in case of medical 
emergency. The dose of intravenous t-PA (predomi- 
nantly single chain preparation, Genentech, Inc.) was 
60 mg over the first hour, with 6 mg as a bolus, 20 mg/ 
hr each for 2 hours, then 10 mg/hr for 5 hours, for a 
total dose of 150 mg. Patients were continuously moni- 
tored for chest pain and considered to reach a clinical 
endpoint if more than 20 minutes of chest pain oc- 
curred, unresponsive to further medical therapy, and 
was associated with electrocardiographic changes. If 
this occurred, the study drug was unblinded and in 
cases of placebo, the patient was considered for cross- 
over to open label t-PA therapy, as outlined. Emergency 
coronary revascularization with either PTCA or 
CABG was used as necessary to treat recurrent ische- 
mic events. 
Follow-up angiography was obtained at 12 to 24 
hours after the initial study. A repeat pacing test was 
performed. If a significant (160%) residual stenosis of 
the “culprit” vesselI was present and the pacing test 
was positive for provocable ischemia, coronary revascu- 
larization was considered to be necessary. Coronary an- 
gioplasty or bypass surgery was performed, depending 
on the underlying coronary anatomy. Results and com- 
plications of the revascularization procedures were re- 
corded. Subsequent to the second angiogram, off-line 
quantitative angiography was performed for the culprit 
artery at baseline, after study drug, and after PTCA, if 
performed, using an automated edge detection comput- 
er algorithm. I4 Angiographic thrombus was defined as a 
definite intracoronary filling defect in at least 2 orthog- 
onal views or total occlusion of the involved artery with 
convex or hazy margins and contrast staining. Quantita- 
tive stenosis and the presence of intraluminal thrombus 
were determined by 2 observers blinded to the patient’s 
identity, therapy and effects of therapy. 
TABLE I Baseline Characteristics” 
t-PA Placebo 
Pts (n) 20 20 
Age (yrs) 58.8 f 2.5 58.1 f 2.2 
Sex (% male) 75 65 
Previous MI 6 8 
Multivessel dlseaset 15 11 
Duration unstable angina (days) 8.8 f 1.7 6.6 f 1.4 
lntracoronary thrombus 7 9 
lschemlc pacing threshold (beats/min) 112 f 4 113 f5 
Diameter stenosis (%) culprit lesion* 71 f4 70 f4 
Culprit vessel 
Left anterior descending 11 11 
Left circumflex 5 4 
Right coronary artery 3 5 
Saphenous vein graft 1 0 
‘There were no slgnlflcant differences (p <0 05) between the 2 groups for any 
baseline characteristic. ’ multwessel disease was defined as 260% stenosis I” a 
nonculprlt. ma,or eplcardnl coronary artery: t by quantltatlve angqraphy. 
MI = myocard!al Infarction 
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Values are expressed as mean f 1 standard devi- 
ation. Characteristics at baseline and clinical outcomes 
were tabulated and compared by the chi-square test or 
Fisher’s exact test for discrete variables and the Student 
t test for continuous characteristics. Clinical endpoints 
were assessed with use of the intention-to-treat princi- 
ple. A sample group of 40 patients was used to deter- 
mine the pacing threshold endpoint, and is the subject 
of a separate report.15 
RESULTS 
Baseline characteristics are summarized in Table 1. 
Of note, the groups were similar for initial quantitative 
stenosis of the culprit lesion and for pacing ischemic 
threshold. During the course of therapy, 4 patients allo- 
cated to receive t-PA and 1 to placebo developed refrac- 
tory ischemia. Of the patients who received t-PA, 1 died 
before urgent repeat angiography, and another died af- 
ter emergency CABG. The placebo group patient with 
refractory ischemia failed emergency PTCA and under- 
went emergency CABG. 
At repeat coronary arteriography, the diameter ste- 
nosis of the culprit artery was 63 f 22% in the patients 
receiving t-PA versus 67 f 22% in placebo group pa- 
tients (p = 0.20). The pacing threshold results have 
been previously reported. I5 To summarize, the threshold 
significantly increased for the patients receiving t-PA 
(112 f 4 beats/min at baseline, mean f standard error 
of the mean; 127 f 5 beats/min after therapy, p = 
0.007) and did not change in the control group (116 f 4 
beats/min at baseline; 119 f 4 beats/min after study 
drug infusion). The patients with angiographically de- 
fined thrombus experienced the most substantial in- 
crease in pacing threshold (increase of 26 f 7 beats/ 
min in patients receiving t-PA vs 0 f 3 beats/min in 
controls, p = 0.004). 
The cumulative rate for coronary revascularization 
procedures, as established by a significant residual ste- 
nosis and a positive test result for pacing-induced ische- 
mia at follow-up catheterization, is as follows: t-PA pa- 
tients, 3 emergency CABG, 4 elective CABG and 8 
T-PA FOR UNSTABLE ANGINA 
elective PTCA; placebo patients, 1 emergency CABG, 7 
elective CABG and 11 elective PTCA. In the placebo 
group, 2 patients underwent both elective PTCA and 
emergency CABG. No significant differences in overall 
rate of PTCA or CABG were present for t-PA com- 
pared with placebo, However, 3 patients treated with t- 
PA compared with none receiving placebo had conver- 
sion to an insignificant residual stenosis (<60’S diame- 
ter by visual criteria) and a negative pacing test (p = 
0.14). 
During PTCA, no patient receiving t-PA experi- 
enced a complication of abrupt closure and 7 of 8 were 
successful, as defined by <50% residual stenosis and 
<20 mm Hg translesional gradient (Figure 1). This 
compares favorably to the 11 placebo group patients 
who underwent PTCA, of whom 3 had abrupt closure 
post-PTCA that could not be managed by pharmaco- 
logic (intracoronary nitroglycerin and streptokinase) or 
mechanical means (prolonged inflations with a 0.5 mm 
larger size balloon at 4 to 6 atmospheres), in 2 patients 
necessitating emergency CABG (p = 0.23). In all 3 pa- 
tients with abrupt closure, filling defects, suggestive of 
intraluminal thrombus formation, were apparent after 
recrossing the lesion and reestablishing flow. The re- 
maining 8 placebo group patients had successful PTCA. 
Bleeding episodes with t-PA or the control group pa- 
tients were not frequent. Periaccess bleeding occurred in 
3 t-PA patients and 2 patients who received placebo. 
Transfusion of 2 or more units of packed cells occurred 
in 5 t-PA patients and no control group patient. The 
indication for transfusion in 4 of the 5 patients receiving 
t-PA was augmentation of hematocrit and in 1 patient 
for observed periaccess site bleeding. 
DISCUSSION 
The results of the current study of intravenous t-PA 
for unstable angina demonstrate the overall high fre- 
quency of definitive coronary revascularization proce- 
dures, but also suggest that t-PA may serve as complete 
therapy in a few patients. Importantly, t-PA appeared 
to promote the safety of the PTCA procedure beyond 
maximal medical therapy including heparin. The con- 
clusions drawn must be tempered, however, due to the 
small population studied. 
Previous angiographic, angioscopic and pathologic 
studies2-4 have documented the importance of coronary 
artery thrombus in unstable angina, but the relative, 
quantitative impact of thrombus compared with the un- 
derlying atherosclerotic plaque remains unclear. After a 
prolonged, high dose infusion of t-PA, the fibrinolytic 
agent with the highest potential to lyse aged throm- 
bus,‘* only slight improvement of quantitative angio- 
graphic stenosis was present and most patients had per- 
sistently positive albeit improved tests for provocable 
(pacing-induced) ischemia. These findings suggest that 
although thrombus plays an integral role for precipitat- 
FIGURE 1. Serial +mgiograms of a patient with unstable angina who was allocated to receive t-PA therapy. A, targe flliing deded 
isnotedinthemidzoneoftherightcoronay artery in the tedt ante&r oblique. B, fobwing t-PA, there is resoWon ot the ttlbng 
Mectbutareskhalstenosisisapparent.C,aftercoronary angbplasty, the residd stenosis is minimal. 
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ing the unstable angina clinical syndromes, most pa- 
tients may still require coronary revascularization, ow- 
ing to either incomplete dissolution of thrombus or the 
underlying high grade atherosclerotic lesion. 
Four patients receiving t-PA had severe, protracted 
ischemia during the course of therapy. Although t-PA 
was associated with overall improvement of the ische- 
mic pacing threshold, the paradoxical clinical deteriora- 
tion noted in these patients may relate to intraplaque 
hemorrhage, as described by Waller et alI6 in patients 
receiving thrombolytic therapy for acute myocardial in- 
farction or as noted by Falk4 in necropsy specimens 
occuring in patients with unstable angina. As in acute 
myocardial infarction, there are likely to be patients 
with unstable angina and intraluminal thrombus who 
are resistant to therapy. I7 No matter the mechanism, it 
is clear that in patients with ischemic pain at rest and 
maximal medical therapy, intravenous t-PA therapy 
does not ensure stabilization and urgent revasculariza- 
tion may be necessary. 
Of note, 3 patients without distinctive demographic 
or angiographic characteristics receiving t-PA had 
marked angiographic resolution of the culprit lesion and 
no longer exhibited pacing-induced ischemia. In con- 
trast to the majority of patients we have discussed, this 
particular group appears to have coronary artery throm- 
bus as the predominant component. Similar findings of 
angiographic resolution of thrombus in patients with 
unstable angina were reported by Bates and Mickel- 
sonI with long-term aspirin therapy. Although such pa- 
tients who derive marked benefit from librinolytic ther- 
apy may be uncommon and difficult to identify prospec- 
tively, avoidance of unnecessary revascularization 
procedures as permitted in this study would be highly 
desirable. 
The results of the current study also support the po- 
tential for t-PA facilitation of the safety of PTCA for 
unstable angina. Avoidance of abrupt closure and the 
need for emergency CABG in t-PA-treated patients 
may have resulted from dissolution of intraluminal 
thrombus. Previous studies from the Mayo Clinic group 
of investigatorsi1’t9 have confirmed the importance of 
angiographically delined thrombus as a risk factor for 
abrupt closure. Review of the published series of PTCA 
in unstable angina patients suggests a relatively high 
rate of myocardial infarction, emergency CABG and in- 
hospital mortality.8-10J3~20-25 Besides the acknowledged 
higher risk of acute complications in these patients, 
there is an increased rate of restenosis after PTCA for 
unstable compared with stable angina, which may also 
relate to coronary artery thrombus.26 Thus, further clin- 
ical investigation to consider improved safety of PTCA 
with t-PA appears warranted. 
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